Although the pathogenic mechanisms of both MS and NMOSD involve peripheral immune responses, NMOSD serum was capable of enhancing the release of mtDNA exclusively in HEK293 cells expressing AQP4, but not in control cells. This evidence concerns the gene AQP4 and myeloid sarcoma.